Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: The ELSIE study

AIM: To evaluate the efficacy and safety of cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer (mCRC) patients from South-East Asia and Australia. METHODS: In this open-label, phase II study, the main eligibility criteria were epidermal growth factor receptor-positive mC...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Lim, Robert, Sun, Yan, Im, Seock-Ah, Hsieh, Ruey-Kuen, Yau, Tsz Kok, Bonaventura, Anthony, Cheirsilpa, Arkom, Esser, Regina, Mueser, Matthias, Advani, Suresh
Format: Artigo
Idioma:Inglês
Publicat: Baishideng Publishing Group Co., Limited 2011
Matèries:
Brief Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3080724/
https://ncbi.nlm.nih.gov/pubmed/21528063
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v17.i14.1879
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars